Access to quality, affordable cancer care is essential for anyone with a cancer diagnosis. Access includes adequate health insurance that covers needed treatments without leaving people with cancer to suffer “financial toxicity.” People with cancer also need the ability to participate in a clinical trial, if it represents a potential treatment option.
Prior to the Affordable Care Act (ACA), cancer survivors were at the mercy of the health care system, often forced to pay exorbitant premiums or simply denied coverage altogether. Today, America’s 17 million cancer survivors benefit from the ACA’s patient protections that provide them with quality, affordable, and accessible health care coverage. Through the ACA, cancer patients and survivors can now purchase insurance through Healthcare.gov and state insurance exchanges. The ACA has afforded protections related to out-of-pocket expenses, lifetime caps, and pre-existing conditions.
NCCS believes in the following principles for access to care:
Individuals with pre-existing conditions must not be denied coverage or charged higher premiums.
Plans must cover all essential health care needs.
Adequate financial assistance must be provided to ensure people with low and moderate incomes can purchase health insurance.
Insurers must not discriminate against older Americans, who are disproportionately impacted by cancer, or women.
Cost-sharing protections must be maintained, including caps on out-of-pocket costs and the elimination of annual and lifetime maximum benefits.
States should take advantage of the ACA’s Medicaid expansion, which provides coverage to low income individuals living with cancer.
People with pre-existing conditions must not be segregated into high-risk pools, which are expensive and burdensome and do not meet the needs of cancer patients.
Cancer patients must have access to comprehensive and well-coordinated cancer care, including clinical trials.
“For a cancer survivor, dealing with the collateral damage of cancer treatment and the continued surveillance for recurrence or secondary cancers, going without insurance is simply not an option. I am very worried that the proposed replacement for the ACA will harm cancer survivors, particularly people with low incomes and people over the age of 50. We simply can’t go back to the days before the ACA when cancer survivors could be denied coverage, and we must ensure people have access to quality, affordable health insurance.”
Michael Kappel, NCCS board member and 13-year colon cancer survivor
https://canceradvocacy.org/wp-content/uploads/2017/10/HHS-Humphrey-bldg-1200.jpg6001200NCCS Staffhttps://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.pngNCCS Staff2021-02-19 15:06:392021-02-24 19:29:10NCCS and Other Cancer Groups Urge HHS to Keep Six Protected Classes in Medicare Part D Drug Plans
https://canceradvocacy.org/wp-content/uploads/CDC-Website.jpg6001200NCCS Staffhttps://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.pngNCCS Staff2021-01-28 22:34:532021-01-28 22:42:08NCCS Urges CDC Committee to Include Cancer Survivors in High-Risk Category for COVID-19 Vaccine Distribution
https://canceradvocacy.org/wp-content/uploads/2017/10/HHS-Humphrey-bldg-1200.jpg6001200NCCS Staffhttps://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.pngNCCS Staff2020-12-22 20:27:262021-01-04 21:38:15NCCS, Cancer Groups Urge CMS to Withdraw Most Favored Nation (MFN) Medicare Part B Rule That Will Harm Patients and Reduce Access to Care
https://canceradvocacy.org/wp-content/uploads/HHS-Humphrey-bldg-1200-1030x515-1.jpg5151030NCCS Staffhttps://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.pngNCCS Staff2020-12-09 17:30:502020-12-10 08:22:55NCCS Letter to HHS: Proposed Regulatory Review Rule Would Create Unnecessary Uncertainty for Patients
https://canceradvocacy.org/wp-content/uploads/HHS-Humphrey-bldg-1200.jpg6001200NCCS Staffhttps://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.pngNCCS Staff2020-12-03 21:26:462020-12-03 21:28:06NCCS Opposes Most Favored Nation (MFN) Rule: New Medicare Part B Drug Payment Model Will Harm Patients
https://canceradvocacy.org/wp-content/uploads/Stovall-Award-2020-feat2.jpg6351200NCCS Staffhttps://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.pngNCCS Staff2020-11-19 01:07:452020-12-04 19:08:17NCCS Presents 5th Annual Ellen L. Stovall Award to Julia H. Rowland, PhD and Thomas J. Smith, MD for Their Innovation and Dedication to Cancer Survivors
The Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care is a unique opportunity for patients and survivors to recognize pioneers who are transforming the cancer care system.
The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.
Share Your Story
NCCS represents the millions of Americans who share a common experience – the survivorship experience – living with, through and beyond a cancer diagnosis.
Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action